

## ***MolMed: Calendar of corporate events for fiscal year 2020***

Milan (Italy), January 29<sup>th</sup> 2020 – MolMed S.p.A. (MLMD.MI), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, announces the calendar of corporate events for fiscal year 2020.

The calendar is available on MolMed’s website ([www.molmed.com](http://www.molmed.com)). Any amendments will be promptly communicated to the market.

### ***Board of Directors***

DATE	SUBJECT
9 March 2020	Approval of draft statutory financial statements for FY 2019
11 May 2020	Approval of interim financial report at 31/03/2020 (*)
27 July 2020	Approval of half-year financial report at 30/06/2020
9 November 2020	Approval of interim financial report at 30/09/2020 (*)

(\*) additional interim financial information

### ***Shareholders’ Meetings***

DATE	SUBJECT
27 April 2020	Approval of statutory financial statements for FY 2019

Under the regulations in force<sup>1</sup> and in order to ensure continuity with the past, MolMed decided to continue the publication of quarterly reports as additional interim financial information (“Additional Info”), on a voluntary basis and until otherwise decided, as already done during fiscal year from 2016 to 2019, with the same form and content to those of the previous fiscal years.

The Additional Info will be subject to approval by the Board of Directors (the “Board”) in meetings to be held within 45 days from the end of the first and third quarter of each fiscal year, and will be disclosed to the market with the same timing, by means of:

- issuance of a press release upon the conclusion of the Board meeting approving the interim financial information;
- publication of the Additional Info on the corporate website ([www.molmed.com](http://www.molmed.com)) within the section devoted to financial reports.

<sup>1</sup> Italian Legislative Decree n. 25/2016 implementing Directive 2013/50/EU (the “Decree”) eliminated the mandatory requirement to publish the quarterly interim financial reports, previously requested pursuant to paragraph 5, art.154-ter of Italian Legislative Decree n. 58/1998 (the “TUF”). The Decree also granted to Consob the powers of providing for any additional disclosure requirements beyond the annual and halfyear financial statements. On the basis of the powers granted by the Decree, Consob - by way of resolution n. 19770 of October 26, 2016 - introduced some amendments to the Issuers’ Regulation concerning additional interim financial information (Article 82-ter), in force from January 2, 2017.



PRESS RELEASE

*About MolMed*

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed's is also developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. The product, whose innovative spacer incorporated in the CAR protein received in May 2019 the confirmation of grant, is potentially effective also in several epithelial solid tumors. MolMed is also developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

*For further information:*

**Ilaria Candotti**

*Investor Relations & Communication Manager*

MolMed S.p.A.

+39 02 21277.205

[investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Tommasina Cazzato**

*Press Office*

Community Group

+39 345 7357751

[tommasina.cazzato@communitygroup.it](mailto:tommasina.cazzato@communitygroup.it)